Does Group Health Cooperative (GHC) Cover Forteo?

GHC Is Now Kaiser Permanente Washington

Group Health Cooperative completed its merger with Kaiser Permanente on February 1, 2017. If you still carry a card that says "Group Health," your coverage is now administered under the Kaiser Permanente Washington umbrella. This distinction matters because formulary decisions, prior authorization criteria, and pharmacy networks all follow Kaiser Permanente's integrated care model.

What Changed After the Merger

Kaiser Permanente Washington maintains its own regional formulary, which is updated quarterly by its Pharmacy and Therapeutics (P&T) Committee. Medications like Forteo fall under the specialty pharmacy benefit rather than the standard prescription drug benefit. The integrated model means your prescribing physician, pharmacy, and insurance review all operate within one system, which can speed up the prior authorization process compared to plans that use external pharmacy benefit managers.

How to Confirm Your Specific Plan

Not every Kaiser Permanente Washington plan is identical. Employer-sponsored group plans, individual marketplace plans, and Medicare Advantage plans each carry different formulary tiers and cost-sharing structures. The most reliable way to verify your Forteo coverage is to log into kp.org/wa, manage to "Pharmacy" and then "Drug Formulary," and search for teriparatide. You can also call Member Services at the number on the back of your insurance card [1].

What Forteo Is and Why It Requires Specialty Coverage

Forteo (teriparatide) is a recombinant form of human parathyroid hormone (PTH 1-34). Unlike bisphosphonates, which slow bone breakdown, teriparatide stimulates new bone formation by activating osteoblasts. The FDA approved teriparatide in 2002 for postmenopausal women and men at high fracture risk, as well as for glucocorticoid-induced osteoporosis [2].

Mechanism and Clinical Evidence

In the key Fracture Prevention Trial (N=1,637), teriparatide 20 mcg/day reduced new vertebral fractures by 65% and nonvertebral fractures by 53% over a median 19-month treatment period compared with placebo [3]. A 2020 Cochrane review confirmed that teriparatide reduces vertebral fracture incidence in postmenopausal women with a relative risk of 0.32 (95% CI 0.19 to 0.54) [4].

Why Insurers Gate Access

Forteo carries a high wholesale acquisition cost. Brand-name Forteo retails near $3,900 per month, and even generic teriparatide (approved by the FDA in 2023) runs approximately $1,200 to $2,000 per month without coverage. Because of the cost and the availability of cheaper oral bisphosphonates as first-line therapy, nearly all commercial and Medicare plans, including Kaiser Permanente Washington, require documentation before approving coverage [5].

Prior Authorization Requirements for Forteo at Kaiser Permanente Washington

Getting Forteo covered under your Kaiser Permanente Washington plan is a multi-step process. The plan uses what is called "step therapy with prior authorization," meaning you must meet specific clinical criteria before the pharmacy will dispense the medication.

Typical Criteria for Approval

Based on standard Kaiser Permanente formulary policies and the American Association of Clinical Endocrinology (AACE) 2020 guidelines, approval generally requires the following [6]:

1. A confirmed diagnosis of osteoporosis, typically via dual-energy X-ray absorptiometry (DXA) showing a T-score of -2.5 or lower at the lumbar spine, femoral neck, or total hip.
2. Documentation of at least one fragility fracture, or a FRAX 10-year major osteoporotic fracture probability exceeding 20%.
3. Failure of, intolerance to, or contraindication for at least one oral bisphosphonate (alendronate or risedronate) over a minimum 12-month trial. "Failure" can mean a new fracture on therapy, continued bone density decline of more than 3% per year, or documented adverse effects such as esophageal ulceration.
4. Adequate calcium (1,000 to 1,200 mg/day) and vitamin D (800 to 1,000 IU/day) supplementation during the bisphosphonate trial.

How to Strengthen Your Authorization Request

Your prescribing clinician submits the prior authorization. The strongest requests include: the DXA report with T-scores, a list of prior osteoporosis medications with start and stop dates, the specific reason each was discontinued, and relevant lab results (serum calcium, 25-hydroxyvitamin D, renal function). Kaiser Permanente Washington's integrated electronic health record means much of this data is already accessible to the reviewing pharmacist, which can shorten turnaround to 24 to 72 hours.

If Your Authorization Is Denied

You have the right to appeal. Kaiser Permanente Washington operates a two-level internal appeal process, followed by an external review through the Washington State Office of the Insurance Commissioner if needed. Your physician can also request an expedited review (decided within 24 hours) if there is clinical urgency, such as a recent vertebral compression fracture.

Cost Breakdown: What You Will Pay Out of Pocket

Even with an approved prior authorization, Forteo sits on the specialty tier of most Kaiser Permanente Washington formularies. Out-of-pocket costs vary by plan type.

Estimated Cost-Sharing by Plan Type

| Plan Type | Typical Monthly Cost for Forteo (After PA) | |---|---| | Employer-sponsored PPO or HMO | $50 to $100 copay per fill | | Individual/Marketplace Silver or Gold | $75 to $150 copay or 20% to 30% coinsurance | | Medicare Advantage | Subject to Part D specialty tier; 25% to 33% coinsurance until catastrophic phase | | Medicaid (Apple Health via KP) | $0 to $3 per fill if on preferred formulary |

These figures are approximate. Your Summary of Benefits and Coverage (SBC) document contains the exact specialty-tier cost-sharing for your plan year.

Generic Teriparatide vs. Brand Forteo

Kaiser Permanente formularies across the country have increasingly moved to preferred status for generic teriparatide over brand Forteo since 2023. If your plan's formulary lists generic teriparatide as preferred, your copay could be 20% to 40% lower than the brand. Ask your prescriber or pharmacist whether a generic substitution is available under your specific plan [7].

Manufacturer and Third-Party Assistance

Eli Lilly, the maker of Forteo, offers the Forteo Savings Card for commercially insured patients, which can reduce copays to as low as $4 per month for eligible individuals. This card does not apply to government-funded plans (Medicare, Medicaid, Tricare). For Medicare patients, the Lilly Cares Foundation Patient Assistance Program may cover the full cost for those who meet income thresholds (generally at or below 300% of the federal poverty level) [8].

Alternatives to Forteo Covered by Kaiser Permanente Washington

If Forteo is not approved, or if the cost-sharing is too high, several alternative osteoporosis treatments are available on the Kaiser Permanente Washington formulary.

Oral Bisphosphonates (First-Line)

Alendronate (generic Fosamax) and risedronate (generic Actonel) are Tier 1 generics on most Kaiser Permanente Washington plans, with copays often under $10 per month. These are the standard first-line treatments recommended by the AACE and the Endocrine Society for patients with osteoporosis [6]. In the Fracture Intervention Trial (FIT, N=2,027), alendronate reduced hip fracture incidence by 51% over three years in women with existing vertebral fractures [9].

Denosumab (Prolia)

Denosumab is a subcutaneous injection given every six months. It is a RANKL inhibitor that reduces bone resorption. The FREEDOM trial (N=7,868) showed denosumab reduced vertebral fractures by 68%, hip fractures by 40%, and nonvertebral fractures by 20% over three years compared with placebo [10]. At Kaiser Permanente Washington, denosumab typically sits on the specialty tier but may have different prior authorization criteria than teriparatide, often requiring only one bisphosphonate failure rather than the more extensive documentation needed for Forteo.

Romosozumab (Evenity)

Romosozumab is a sclerostin inhibitor approved in 2019 for postmenopausal women at very high fracture risk. In the ARCH trial (N=4,093), romosozumab followed by alendronate reduced new vertebral fractures by 48% compared with alendronate alone over 24 months [11]. Coverage requires prior authorization and is limited to patients with very high fracture risk, a history of multiple fractures, or T-scores below -3.0. A cardiovascular risk screening is also required given the boxed warning for major adverse cardiac events.

Abaloparatide (Tymlos)

Abaloparatide is another parathyroid hormone-related peptide analog, similar in mechanism to teriparatide. The ACTIVE trial (N=2,463) showed abaloparatide reduced new vertebral fractures by 86% versus placebo over 18 months [12]. It is an alternative if teriparatide is specifically not covered or not tolerated. Formulary placement varies by plan year.

Zoledronic Acid (Reclast)

Zoledronic acid is an intravenous bisphosphonate given once yearly. The HORIZON-PFT trial (N=7,765) demonstrated a 70% reduction in vertebral fractures and a 41% reduction in hip fractures over three years [13]. Because it is administered in a clinical setting (infusion center), it falls under the medical benefit rather than the pharmacy benefit at Kaiser Permanente Washington. This means cost-sharing follows your plan's outpatient procedure copay or coinsurance, not the prescription drug tier structure.

How to Manage the Coverage Process Step by Step

Getting Forteo covered through Kaiser Permanente Washington follows a predictable workflow. Knowing each step can reduce delays.

Step 1: Get a Current DXA Scan

Ensure your bone density scan is less than 24 months old. If your most recent DXA is older, request a new one before your prescriber submits the prior authorization. Kaiser Permanente Washington operates its own imaging centers, so scheduling is typically faster than with external referrals.

Step 2: Document Your Treatment History

Work with your prescriber to compile a clear record of all prior osteoporosis treatments, including specific drug names, dosages, durations, and outcomes. If you experienced side effects from a bisphosphonate, make sure those are documented in your chart with the date of onset and the clinical decision to discontinue.

Step 3: Submit the Prior Authorization

Your prescriber or their staff submits the request through Kaiser Permanente Washington's internal pharmacy authorization system. Routine requests are typically reviewed within 48 to 72 hours. Urgent requests (recent fracture, rapidly declining bone density) can be expedited.

Step 4: Fill Through Kaiser Permanente Specialty Pharmacy

If approved, Forteo is dispensed through Kaiser Permanente's own specialty pharmacy. The medication ships directly to your home or can be picked up at select Kaiser Permanente pharmacies. A specialty pharmacist will provide injection training during your first fill.

Step 5: Monitor and Reauthorize

Forteo authorization is typically granted for 12 months at a time, with a maximum treatment duration of 24 months per the FDA label. Your prescriber will need to submit a reauthorization request before the second year, confirming ongoing clinical need and monitoring data (bone turnover markers, any new fractures, calcium levels).

Important Safety and Duration Limits

The FDA limits teriparatide use to a cumulative 24 months based on preclinical data showing osteosarcoma in rats exposed to high doses over their lifetimes. While no causal link has been established in humans (post-marketing surveillance through 2020 found no signal above background rates), the 24-month cap remains on the label [14]. After completing a teriparatide course, patients should transition to an antiresorptive agent (bisphosphonate or denosumab) to maintain bone density gains. The DATA-Switch study showed that bone mineral density gains from teriparatide were partially lost within 12 months if no follow-up antiresorptive was started [15].

Serum calcium monitoring is recommended during the first months of therapy. Hypercalcemia occurs in approximately 11% of patients on teriparatide, though clinically significant elevations are rare. Patients with pre-existing hypercalcemia, Paget's disease, unexplained alkaline phosphatase elevation, prior skeletal radiation, or open epiphyses should not receive teriparatide [2].

Washington State Protections for Osteoporosis Coverage

Washington State has specific insurance regulations that may support your coverage request. Under RCW 48.43.045, health plans issued in Washington must provide coverage for osteoporosis screening for high-risk individuals. While this statute does not mandate coverage for any specific osteoporosis medication, it establishes a regulatory framework that recognizes osteoporosis treatment as medically necessary care. The Washington State Office of the Insurance Commissioner can assist with external appeals if your plan denies coverage for a medication your physician deems clinically necessary [16].